학술논문
Comparative Clinical Study of Ceftazidime and Cefotiam for Respiratory Tract Infections by a Double-blind Method / 呼吸器感染症に対するCeftazidimeとCefotiamとの薬効比較試験成績
Document Type
Journal Article
Author
Akihiko KISHIMOTO; Akira ITO; Akira SAITO; Akira SUZUKI; Akira WATANABE; Asako YAMAMOTO; Atsushi SAITO; Eiji KANETO; Eiro TSUBURA; Fukuo IIJIMA; Fumio MATSUMOTO; Fumio MIKI; Fumio TANAKA; Fusanosuke YAMASAKU; Fuyuhiko HIGASHI; Gen ENOOKA; Hajimu TAKEDA; Hideki SASAKI; Hideo IKEMOTO; Hideo SASAKI; Hideya MURABAYASHI; Hideyuki HASEGAWA; Hiroichi TANIMOTO; Hiromaru IWASAKI; Hiromi KIHARA; Hiromichi HORIKAWA; Hironobu IHARA; Hiroshi OKUBO; Hiroshi TAKAHASHI; Hirotada IKEDA; Hiroyoshi ISHIBASHI; Hiroyuki KAWAHARA; Hiroyuki KOBAYASHI; Hitoshi NAGANO; Ichiro NAKAYAMA; Ippei FUJIMORI; Isao NAKAMURA; Isao NITTA; Izumi HAYASHI; Jingoro SHIMADA; Jun CHIBA; Jun GOTO; Junichi SUETSUNA; Junzaburo KABE; KOUJIN KIN; Kaneo SUZUKI; Kanzo SUZUKI; Kaoru OKADA; Kaoru OYAMA; Kaoru SHIMADA; Katsuhiro OKAMOTO; Kazufuto FUKAYA; Kazuhiro OKUNO; Kazuma FUJINO; Kazumine KOBARI; Kazuo TAKEBE; Kazuyoshi WATANABE; Keigo MAEHARA; Keiichi NAKAGAWA; Keiji TAKAHASHI; Keimei MASHIMO; Keizo MATSUMOTO; Keizo YAMAGUCHI; Kenji MARUMO; Kenji TAKAMURA; Kikuo ONUMA; Kiyo NISHIOKA; Kiyoshi KONNO; Kohei HARA; Kohki KIKUCHI; Kohta KOHNO; Kohu MUROHASHI; Kohya SHIBA; Koichiro NAKATA; Kojiro YASUNAGA; Kokichi FUKUSHIMA; Kotaro OIZUMI; Kunihiko SHINDO; Kunihiko YOSHIMURA; Kuninori SUZUKI; Kunio NOMURA; Kyoko URAYAMA; Kyoko WATANABE; Makio KURIHARA; Masakazu TAMURA; Masako SASAKI; Masao MIKITANI; Masao NAKATOMI; Masaro KAJI; Masaru KOYAMA; Masaru NASU; Masataka KATSU; Masumi TOMIZAWA; Mieko KAWAI; Mitsunari NAKAMURA; Mitsunobu HONMA; Mitsuo ASAKAWA; Morio SAGARA; Muneto YOSHIOKA; Naohiko CHONABAYASHI; Naoki TAMAZAWA; Naoyoshi MASAKI; Nobuaki SHIGEMATSU; Nobuki AOKI; Nobuyuki HIROSE; Osamu KURIHARA; Osamu SEKINE; Osamu UEHARA; Rinzo SOEJIMA; Ryuji AKIYOSHI; Ryusaku SHIMIZU; Seiichi AONUMA; Seiji MITA; Shigeki ODAGIRI; Shigeru KOHNO; Shigeru TAMAKI; Shigetake MIYAZAKI; Shigetoshi YANAGIYA; Shinji OKUI; Shinya YASUDA; Shiro IDA; Shohei NAGAOKA; Shoji YASUI; Shuichiro YOSHIDA; Syunji HAYASHI; Tadashi MIYAHARA; Takahisa SAITO; Takashi INAMATSU; Takashi ITOGA; Takashi YAMAMOTO; Takehisa YAMAJI; Takehito NAKABAYASHI; Takeshi ISHIZAKI; Taketsune MATSUMOTO; Tamotsu KANEKO; Tamotsu TAKISHIMA; Tatsuo NAKATANI; Tatsuya ABE; Tetsuji KOROKU; Tetsuro UKAI; Tomio ONUMA; Tomohiro KANAZAWA; Tomoyuki HARADA; Toshihiro GOTO; Toshiro ODA; Toshiyuki YAMAMOTO; Toyokazu TAMURA; Tsunetoshi KOTEDA; Tsutomu YAMAZAKI; Yasuko YUASA; Yasushi UEDA; Yasutoshi SUZUKI; Yasuyuki SANO; Yoichiro ICHIKAWA; Yoji SUZUYAMA; Yomei HIRAGA; Yoshihiko ARATANI; Yoshihiro UEDA; Yoshihito NIKI; Yoshimaru USUDA; Yoshio AOKI; Yoshio KOBAYASHI; Yoshiro ISHII; Yoshiro SAWAE; Yoshitaka NAKAMORI; Yoshiteru SHIGENO; Yoshiyuki MITSUTAKE; Yube IIDA; Yukio KUMAGAI; Yuruko OKAMOTO; Yutoku KINJO; 三木 文雄; 三木谷 政夫; 上原 修; 上田 泰; 上田 良弘; 中富 昌夫; 中山 一朗; 中川 圭一; 中村 光成; 中村 功; 中林 武仁; 中森 祥隆; 中田 紘一郎; 中谷 龍王; 丸茂 健治; 二木 芳人; 井原 裕宣; 井田 士朗; 今野 淳; 伊藤 章; 佐々木 昌子; 佐々木 秀樹; 佐々木 英夫; 佐野 靖之; 光武 良幸; 前原 敬悟; 副島 林造; 加地 正郎; 勝 正孝; 千場 純; 原 耕平; 原田 知行; 可部 順三郎; 吉岡 宗; 吉村 邦彦; 吉田 秀一郎; 堀川 博道; 大久保 滉; 大山 馨; 大沼 菊夫; 大泉 耕太郎; 奥井 津二; 奥野 一裕; 安井 昭二; 安永 幸二郎; 安田 悳也; 室橋 光宇; 宮原 正; 宮崎 重武; 富沢 磨須美; 小六 哲司; 小山 優; 小張 一峰; 小林 宏行; 小林 芳夫; 小沼 富男; 小田 俊郎; 小田切 繁樹; 山作 房之輔; 山口 恵三; 山崎 力; 山本 俊幸; 山本 敬; 山本 朝子; 山路 武久; 岡本 勝博; 岡本 緩子; 岡田 薫; 岩崎 博円; 岸本 明比古; 島田 馨; 嶋田 甚五郎; 市川 洋一郎; 平賀 洋明; 広瀬 宣之; 後東 俊博; 後藤 純; 斉藤 孝久; 斎藤 厚; 斎藤 玲; 斎藤 篤; 新田 功; 木原 広美; 末綱 純一; 本間 光信; 村林 秀哉; 東 冬彦; 松本 慶蔵; 松本 文夫; 松本 武典; 林 俊治; 林 泉; 柳谷 重利; 柴 孝也; 柾木 尚義; 栗原 牧夫; 栗村 統; 武田 元; 武部 和夫; 池本 秀雄; 池田 大忠; 沢江 義郎; 河原 弘規; 河合 美枝子; 河野 浩太; 河野 茂; 浅川 三男; 浦山 京子; 深谷 一太; 清水 隆作; 渡辺 一功; 渡辺 京子; 渡辺 彰; 湯浅 保子; 滝島 任; 熊谷 幸雄; 猪岡 元; 玉木 重; 玉沢 直樹; 田中 二三郎; 田村 正和; 田村 豊一; 相楽 衛男; 真下 啓明; 石井 禎郎; 石崎 驍; 石橋 弘義; 福島 孝吉; 秋吉 龍二; 稲松 孝思; 籠手田 恒敏; 糸賀 敬; 美田 誠二; 荒谷 義彦; 菊地 弘毅; 薄田 芳丸; 藤森 一平; 藤野 和馬; 蝶名林 直彦; 螺良 英郎; 西岡 きよ; 谷本 普一; 進藤 邦彦; 那須 勝; 重松 信昭; 重野 芳輝; 野村 邦雄; 金 衡仁; 金城 勇徳; 金子 保; 金澤 知博; 金藤 英二; 鈴山 洋司; 鈴木 周雄; 鈴木 国功; 鈴木 幹三; 鈴木 康稔; 鈴木 明; 長岡 章平; 長谷川 英之; 長野 準; 関根 理; 阿部 達也; 青木 信樹; 青木 良雄; 青沼 清一; 飯島 福生; 飯田 夕; 高村 研二; 高橋 寛; 高橋 敬治; 鵜飼 徹朗
Source
感染症学雑誌 / Kansenshogaku Zasshi. 1984, 58(7):663
Subject
Language
Japanese
ISSN
0387-5911
1884-569X
1884-569X
Abstract
For objective evaluation of the efficacy and safety of ceftazidime (CAZ), a new cephem antibiotic, in respiratory tract infections, a double blind comparative study was carried out against cefotiam (CTM). Either of the drugs was administered by intravenous drip infusion in the unit dose of 1 g (potency) twice daily for 14 days, and the following results were obtained.1. In the assessment by the efficacy Assessment Committee, the overall clinical efficacy rate was 73.2%(90/123) in the CAZ group and 72.0%(90/125) in the CTM group, with no statistically significant difference between the two treatments. When reviewed for each diagnosis, the efficacy rate was slightly lower in the CAZ group than that in the CTM group 60.6%(40/66) and 74.2%(49/66), respectively, in bacterial pneumonia and lung abscess, although there was no significant difference between the two treatments. Whereas in chronic RTI the efficacy rate was higher in the CAZ group (86.0%, 43/50) than that in the CTM group (66.7%, 36/54) with significant difference (χ2-test, <0.05).2. In the assessment by the physicians in charge, the overall clinical efficacy rate for all cases was 70.7%(104/147) in the CAZ group and 63.7%(101/147) in the CTM group, with no significant difference between the two treatments. When reviewed for each diagnosis, efficacy rate was 70.1%(68/97) in the CAZ group and 71.7%(66/92) in the CTM group in the treatment of bacterial pneumonia and lung abscess, and there was statistically no significant difference between the two treatments. In chronic RTI, the efficacy rate in the CAZ group (79.5%, 35/44) tended to be higher than that in the CTM group (66.7%, 34/51) (U-test, p<0.10).3. In the 112 cases (55 cases in the CAZ group, 57 cases in the CTM group) in which the bacteriological response could be assessed, elimination of bacteria was achieved in more cases in the CAZ group than in the CTM group, with significant difference (U-test, χ2-test, p<0.01). As to the eradication rate including “replaced”, there was no statistically significant difference between the two treatments.4. As far as the incidence of side effects and abnormal laboratory findings were concerned, there was no significant difference between the two treatments.5. The Committee assessed the overall utility (efficacy + safety) as 84.0%(42/50) in the CAZ groupand 66.7%(36/54) in the CTM group in chronic RTI, and the utility in the CAZ group tended to be higher than that in the CTM group (χ2-test, p<0.10). In other diagnoses and also in all cases, there was no significant difference between the two treatments. In the assessment by the physicians in charge, there was no significant difference between the two drugs in the utility.From the above results, CAZ was considered to be as useful as CTM, based on the efficacy and safety in respiratory tract infections.